Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News

Who Will Survive the Biotech VC Downturn? The Young and the Proven 



October 23, 2012 - (Xconomy) - "Given how long it takes for a biotech fund to mature, partners in their 60s today may not want to sign up for another go-round that requires they work full-throttle into their mid-70s. So, I’ve been wondering lately which biotech VCs are the most likely to keep investing for at least another 10 to 20 years." Read Full Article


Posted on 13-Nov-12 by Gallerno, Jacob
Tags: Science and Industry News
Trackback Url  |  Link to this post | Bookmark this post with: